Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per specialist: David Cunningham
Woman and Man Max 99 years
David Cunningham, MD
Update Il y a 4 ans
Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment
The purpose of this this trial is to prove the efficacy and safety of MGN1703 as a maintenance therapy after first-line chemotherapeutic treatment of metastatic colorectal cancer.
Country
None
organs
None
Specialty
None
Opened trial
More information
University College London (UK)
Update Il y a 4 ans
A phase III multicentre randomised clinical trial comparing rituximab with cyclophosphamide, doxorubicin, vincristine and prednisone given every 14 days and rituximab with cyclophosphamide, doxorubicin, vincristine and prednisone given every 21 days for the treatment of patients with newly diagnosed diffuse large B cell non-Hodgkin's lymphoma
http://www.cancerhelp.org.uk/trials/a-trial-looking-at-treatment-every-2-weeks-or-every-3-weeks-for-non-hodgkins-lymphoma
Country
United Kingdom
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
David Cunningham, MD, FRCP
Update Il y a 4 ans
Combining Erlotinib Plus Bevacizumab and Gemcitabine Plus Capecitabine to Treat Advanced Pancreatic Cancer
Pancreatic cancer is an aggressive, largely chemo-resistant disease with a poor prognosis. EGFR and VEGF are both overexpressed in pancreatic cancers and thought to contribute to tumour de...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
David Cunningham
Update Il y a 4 ans
Gemcitabine and Oxaliplatin (Gem-Ox) Plus Glivec in Gemcitabine-refractory Pancreatic Cancer
The main research objective is to work out the optimal doses of the novel combination of gemcitabine, oxaliplatin and imatinib mesylate (glivec) in patients with advanced pancreatic cancer...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Sanofi-Aventis Research Grant
Update Il y a 4 ans
A phase II/III randomised trial comparing Epirubicin, Cisplatin and Protracted Venous Infusion (PVI) 5-Fluorouracil (5-FU) (ECF), Epirubicin, Oxaliplatin and PVI 5-FU (EOF), Epirubicin, Cisplatin and Capecitabine (ECX) and Epirubicin, Oxaliplatin and Capecitabine (EOX) in Patients with Advanced Oesophago-Gastric Cancer
Not provided at time of registration
Country
United Kingdom
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
David Cunningham, MD FRCP
Update Il y a 4 ans
Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer
During this open label study patients will receive IMM-101 in conjunction with a recognised standard of care for metastatic or unresectable cancer for the patient's specific tumour type. ...
Country
None
organs
None
Specialty
None
Opened trial
More information
Woman and Man Max 99 years
David Cunningham
Update Il y a 4 ans
Study of PEP02, Irinotecan or Docetaxel in Gastric or Gastroesophageal Junction Adenocarcinoma
The purpose of this study is to assess objective tumor response in the single agent treatment of PEP02, irinotecan, or docetaxel for locally advanced or metastatic gastric or gastroesophag...
Country
Bosnia and Herzegovina
,
Croatia
,
Korea, Republic of
,
Spain
,
Taiwan, Province of China
,
United Kingdom
organs
None
Specialty
None
Closed trial
More information
Previous
1
2
3